Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 25, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements on July 17, 2006, executed by the SmithKline Beecham Employee Benefit Trust ("the Trust") on behalf of participants in the GlaxoSmithKline Annual Investment Plan:
- Sale: 453 Ordinary shares were sold at a price of GBP 14.73 per share.
- Transfer: 645 Ordinary shares were transferred from the Trust to a participant.
Director Mr. J S Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the reported transactions.
- Confirm the current share price relative to the GBP 14.73 transaction price reported for July 17, 2006.
- Review the full composition of the Trust to understand the scope of Director J S Heslop's indirect interest.